Gyros and DI Biotech Sign Distribution Agreement for the Korean Market

December 10, 2009

Gyros AB (Uppsala, Sweden), a provider of automated micro-immunoassays for therapeutic protein development, has signed a distribution agreement with DI Biotech (Seoul, Korea), a supplier to the Korean life sciences market.

Gyros AB (Uppsala, Sweden), a provider of automated micro-immunoassays for therapeutic protein development, has signed a distribution agreement with DI Biotech (Seoul, Korea), a supplier to the Korean life sciences market. Under the terms of the agreement, DI Biotech will market and provide full support for Gyros’s proprietary technology, Gyrolab, to the Korean pharmaceutical, biotechnology, CRO, and CMO industries.

Gyrolab is Gyros’s automated and open platform, an analytical tool that reduces the time required to optimize and execute immunoassays. This reduction results in increased efficiency in process development and in clinical evaluation of therapeutic proteins. Gyrolab enables assays to be conducted with a reduced background, four-log dynamic range, and with higher throughput, using only nanoliter volumes of critical reagents and sample.